Basic Information
| LncRNA/CircRNA Name | TSLD8 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RIP |
| Sample | cell lines SMMC-7721, Huh7, HepG2, Hep3B, L02 and HEK293T, HCC tissues compared with normal adjacent ones |
| Expression Pattern | down-regulated |
| Function Description | TSLD8 expression is significantly lowered in HCC tissues and cell lines. TSLD8 facilitates migration and viability in SMMC-7721 and HepG2 cells. Furthermore, TSLD8 can interact with WWOX and protect WWOX from proteasome-mediated degradation. Using PuPGEA-based nanocomplex for gene delivery, we found that co-delivery of TSLD8 and WWOX may exhibit synergistic and additive effects to inhibit HCC progression. PuPGEA-based nanocomplex delivery does not substantially alter the blood chemistries (e.g. alkaline phosphatase, blood urea nitrogen, aspartate aminotransferase, alanine aminotransferase) or initiate immune responses implying a safe strategy. |
| Pubmed ID | 31230746 |
| Year | 2019 |
| Title | A long non-coding RNA TSLD8 inhibits hepatocellular carcinoma by stabilizing WWOX |
External Links
| Links for TSLD8 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |